FIELD: pharmacy. SUBSTANCE: invention relates to oral pharmaceutical composition exhibiting the controlled drug release. Composition has 10-160 mg oxycodone or its salt and provides mean-maximal oxycodone concentration in plasma in vivo up to 240 ng/ml in 2-4.5 h after administration and mean-minimal concentration of oxycodone in plasma in vivo up to 120 ng/ml in 10-14 h after repeated administration each 12 h at stationary condition. New oral pharmaceutical composition is made as a solid medicinal form and has analgetically effective amount of spheroids, sphere-forming agent and film cover regulating oxycodone or oxycodone salt release at the controlled rate. Solid oral medicinal form as a tablet is preferable. New compositions provide the pain relief in 90% patients at significant dose level decrease. EFFECT: enhanced effectiveness of composition. 11 cl, 5 dwg, 18 tbl, 19 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION, CONTAINING OPIOID ANTAGONIST FOR TREATMENT OF URINARY RETENTION | 2009 |
|
RU2478388C2 |
OXICODON AND NALOXON-CONTAINING PHARMACEUTICAL COMPOSITIONS WITH INSTANT RELEASE | 2010 |
|
RU2522212C2 |
PHARMACEUTICAL PREPARATION CONTAINING OXYCODON AND NALOXON | 2003 |
|
RU2295344C2 |
COMPOSITIONS CONTAINING ENZYMATIC DECOMPOSABLE OXYCODONE PRODRUG | 2012 |
|
RU2609412C2 |
METHOD FOR PREVENTION ABUSE WITH OPIOID- -CONTAINING MEDICINAL FORMULATIONS | 1998 |
|
RU2228180C2 |
HYDROCODON PREPARATIVE SUSTAINED-RELEASE FORMULATIONS | 2000 |
|
RU2230556C2 |
BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYCODONE | 2015 |
|
RU2683317C2 |
DRUG FORM CONTAINING OXYCODON AND NALOXON | 2006 |
|
RU2428985C2 |
COMBINATIONS OF AGONIST/ANTAGONIST FOR OPIOID | 1998 |
|
RU2241458C2 |
MATRIX PROVIDING PROLONGED, INVARIANT, AND INDEPENDENT RELEASING OF ACTIVE SUBSTANCES | 2003 |
|
RU2297225C2 |
Authors
Dates
1998-11-27—Published
1992-11-25—Filed